A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016

PharmacoEconomics

Volumn 35, Issue 2, 2017, Pages 215-223

  McRae, Jacquelyn ^a   Vogenberg, F Randy ^b   Beaty, Silky Webb ^c   Mearns, Elizabeth ^d   Varga, Stefan ^a   Pizzi, Laura ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Institute for Integrated Healthcare   (United States)

^c Express Scripts   (United States)

^d IBM WATSON HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

CONSUMER; DRUG COST; DRUG MARKETING; DRUG SHORTAGE; HUMAN; MANAGED CARE; MEDICAID; MEDICARE; MEDLINE; OUTPATIENT; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; UNITED STATES; ECONOMICS; HEALTH CARE POLICY; HEALTH INSURANCE; INSURANCE; PHARMACOECONOMICS;

DRUG COSTS; ECONOMICS, PHARMACEUTICAL; HUMANS; INSURANCE CARRIERS; INSURANCE, PHARMACEUTICAL SERVICES; MEDICAID; MEDICARE; PATIENT PROTECTION AND AFFORDABLE CARE ACT; PRESCRIPTION DRUGS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 84992694377     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-016-0458-0     Document Type: Review

References (55)

1. Shi L, Singh D. Delivering health care in America. 6th ed. Burlington: Jones & Bartlett Learning; 2015.
2. Kaiser Permanente. Our history. 2016. https://share.kaiserpermanente.org/article/history-of-kaiser-permanente/. Accessed 27 Jul 2016.
3. Source book of health insurance data, 1999–2000. Washington: Health Insurance Association of America; 1999.
4. Enthoven AC, Fuchs VR. Employment-based health insurance: past, present, and future. Health Aff (Millwood). 2006;25(6):1538–47.
5. Blumenthal D. Employer-sponsored health insurance in the United States—origins and implications. N Engl J Med. 2006;355(1):82–8.
6. McDonnell K. History of health insurance benefits. Employment Benefit Research Institute; 2002. https://www.ebri.org/publications/facts/index.cfm?fa=0302fact. Accessed 27 Jul 2016.
7. Employer Health Benefits Survey. The Kaiser Family Foundation; 2013. http://kff.org/private-insurance/report/2013-employer-health-benefits/. Accessed 27 Jul 2016.
8. Medicare.gov. Your Medicare coverage: prescription drugs (outpatient). 2016. https://www.medicare.gov/coverage/prescription-drugs-outpatient.html. Accessed 27 Jul 2016.
9. Boukus ER, Carrier ER. Americans’ access to prescription drugs stabilizes, 2007–2010. Tracking report. Center for Studying Health System Change. 2011 Dec; No. 27. http://www.hschange.org/CONTENT/1264/1264.pdf. Accessed 24 Aug 2016.
10. Levinson DR. Replacing average wholesale price: medicaid drug payment policy. Department of Health & Human Services, Office of Inspector General; 2011. OEI-03-11-00060. http://www.oig.hhs.gov/oei/reports/oei-03-11-00060.pdf. Accessed 27 Jul 2016.
11. Wilke RJ. Beyond AWP… way beyond. Value Health. 2010;13(1):1.
12. Anderson L. Average wholesale price (AWP) as a pricing benchmark. 2014. https://www.drugs.com/article/average-wholesale-price-awp.html. Accessed 18 Oct 2016.
13. Settlement of conspiracy case forces major restructuring of prescription drug-pricing system. Prescription Access Litigation; 2006. http://www.dc37.net/news/newsreleases/2006/PALdrugpricing.pdf. Accessed 27 Jul 2016.
14. Curtiss FR, Lettrich P, Fairman KA. What is the price benchmark to replace average wholesale price (AWP)? J Manag Care Pharm. 2010;16(7):492–501.
15. Levinson DR. Medicaid drug price comparisons: average manufacturer price to published prices. Department of Health & Human Services, Office of Inspector General; 2005. OEI-05-05-00240. http://www.oig.hhs.gov/oei/reports/oei-05-05-00240.pdf. Accessed 30 Jul 2016.
16. Department of Health and Human Services. Medicaid program; covered outpatient drugs; final rule. Federal Register. 2016 Feb 1. https://www.gpo.gov/fdsys/pkg/FR-2016-02-01/pdf/2016-01274.pdf. Accessed 27 Jul 2016.
17. Health Resources and Services Administration. 340B Drug Pricing Program: eligibility & registration. http://www.hrsa.gov/opa/eligibilityandregistration/index.html. Accessed 27 Jul 2016.
18. Levinson D. State Medicaid policies and oversight activities related to 340B-purchased drugs. Department of Health and Human Services, Office of Inspector General; 2011 Jun. http://www.hrsa.gov/opa/programrequirements/reports/medicaidpoliciesandoversities062011.pdf. Accessed 15 Jul 2016.
19. Report to the congress: overview of the 340B Drug Pricing Program. MedPAC; 2015 May. http://www.medpac.gov/docs/default-source/reports/may-2015-report-to-the-congress-overview-of-the-340b-drug-pricing-program.pdf?sfvrsn=0?. Accessed 29 Jul 2016.
20. Wachino V. RE: implementation of the covered outpatient drug final regulation provisions regarding reimbursement for covered outpatient drugs in the Medicaid program [letter]. Department of Health and Human Services; 2016 Feb 11. https://www.medicaid.gov/federal-policy-guidance/downloads/smd16001.pdf. Accessed 18 Oct 2016.
21. Myers and Stauffer LC. Alabama pharmacy: FAQs. http://www.mslc.com/Alabama/PharmacyFAQs.aspx. Accessed 27 Jul 2016.
22. Medicaid.gov. Affordable Care Act federal upper limit methodology and data elements guide. 2016. https://www.medicaid.gov/medicaid-chip-program-information/by-topics/prescription-drugs/true-up/xxxxxdraft-true-up-methodology.pdf. Accessed 27 Jul 2016.
23. Mullen P. The arrival of average sale price. Biotechnol Healthc. 2007;4(3):48–53.
24. Giled S, Haninger K. Medicare Part B reimbursement of prescription drugs. ASPE Issue Brief. US Department of Health and Human Services; 2014 Jun 1. https://aspe.hhs.gov/report/medicare-part-b-reimbursement-prescription-drugs. Accessed 24 Sep 2016.
25. Medicare Part B drug average sales price: manufacturer reporting of average sales price (ASP) data. Center for Medicare & Medicaid Services; 2016. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html?redirect=/mcrpartbdrugavgsalesprice/10_vaccinespricing.asp. Accessed 27 Jul 2016.
26. MAC pricing incents more affordable Rx. Express Scripts; 2016. http://lab.express-scripts.com/lab/insights/drug-options/mac-pricing-incents-more-affordable-rx. Accessed 27 Jul 2016.
27. Social Security Office. Use of the average sales price methodology. 42 U.S.C. § 1395w-3a(c). https://www.ssa.gov/OP_Home/ssact/title18/1847A.htm. Accessed 29 Sep 2016.
28. Medicaid.gov. Medicaid Drug Rebate Program. 2016. https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html. Accessed 27 Jul 2016.
29. Pharmacy Benefit Management Institute (PBMI). 2016 trends in specialty drug benefits report. 2016 Mar. https://www.pbmi.com/shop/specialty-drug-benefit-reports/2016-specialty-drug-benefit-report/. Accessed 29 Sep 2016.
30. Connole P. Pay-for-value movement turns attention to prescription drugs. Atlantic Information Services; 2015. https://aishealth.com/archive/nhpw071315-04. Accessed 15 Jun 2016.
31. Tonks A. Merck offers money back guarantee on finasteride. BMJ. 1994;309:1252–3. doi:10.1136/bmj.309.6964.1252a.
32. Deloitte. Value-based pricing for pharmaceuticals: implications of the shift from volume to value. 2015. http://www.converge-health.com/sites/default/files/uploads/resources/white-papers/valuebasedpricingpharma_060412.pdf. Accessed 27 Jul 2016.
33. Matthius A. Novartis strikes pay-for-performance deals for heart-failure drug Entresto. PM360; 2016 Feb. https://www.pm360online.com/novartis-strikes-pay-for-performance-deals-for-heart-failure-drug-entresto/. Accessed 27 Jul 2016.
34. The Henry J. Kaiser Family Foundation. Summary of the Affordable Care Act. 2013. http://kff.org/health-reform/fact-sheet/summary-of-the-affordable-care-act/. Accessed 27 Aug 2016.
35. Center for Medicare & Medicaid Services. About the CMS Innovation Center. 2016. https://innovation.cms.gov/About/index.html. Accessed 27 Jul 2016.
36. The Maryland Health Services Cost Review Commission. Maryland All-Payer Model agreement. 2014. http://www.hscrc.state.md.us/documents/md-maphs/stkh/MD-All-Payer-Model-Agreement-(executed).pdf. Accessed 27 Jul 2016.
37. Centers for Medicare and Medicaid Services. Medicare Part B Drugs Payment Model. 2016. https://innovation.cms.gov/initiatives/part-b-drugs. Accessed 18 Oct 2016.
38. MedPAC. Ch. 3: Part B drug payment policy issues. Report to the Congress: Medicare and the health care delivery system. 2015. http://www.medpac.gov/documents/reports/chapter-3-part-b-drug-payment-policy-issues-(june-2015-report).pdf?sfvrsn=0. Accessed 27 Jul 2016.
39. CMS.gov. At risk: pre-existing conditions could affect 1 in 2 Americans: 129 million people could be denied affordable coverage without health reform. The Center for Consumer Information & Insurance Oversight. https://www.cms.gov/CCIIO/Resources/Forms-Reports-and-Other-Resources/preexisting.html. Accessed 3 Oct 2016.
40. Obamacare Facts. Obamacare facts: an independent site for ACA advice. http://obamacarefacts.com. Accessed 27 Jul 2016.
41. Pearson C. Avalere analysis: exchange benefit designs increasingly place all medications for some conditions on specialty drug tier. Avalere Health An Innovation Company. http://avalere.com/expertise/life-sciences/insights/avalere-analysis-exchange-benefit-designs-increasingly-place-all-medication. Accessed 27 Jul 2016.
42. Goldman D, Joyce G, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61–9.
43. Ollove M. States limiting patient costs for high-priced drugs. The Pew Charitable Trusts; 2015 Jul 2. http://www.pewtrusts.org/en/research-and-analysis/blogs/stateline/2015/07/02/states-limiting-patient-costs-for-high-priced-drugs. Accessed 18 Oct 2016.
44. Reinke T. Benefit and formulary options appear in specialty pharmacy. Managed Care; 2014. http://www.managedcaremag.com/archives/2014/1/benefit-and-formulary-options-appear-specialty-pharmacy. Accessed 4 Sep 2016.
45. ASHP Expert Panel on Drug Product Shortages, Fox ER, Birt A, James KB, Kokko H, Salverson S, et al. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009;66:1399–406.
46. Fox E. National drug shortages. University of Utah Drug Information Services; The American Society of Health-System Pharmacists; 2016. http://www.ashp.org/menu/DrugShortages. Accessed 27 Jul 2016.
47. PhRMA. Drug shortages and supply chain info. http://www.phrma.org/drug-shortages. Accessed 27 Jul 2016.
48. Pollack A. Drug goes from $13.50 a tablet to $750, overnight. New York Times. 2015 Sep 20. http://www.nytimes.com/2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html?_r=0. Accessed 27 Jul 2016.
49. Pollack A. Big price increase for tuberculosis drug is rescinded. New York Times. 2015 Sep 21. http://www.nytimes.com/2015/09/22/business/big-price-increase-for-tb-drug-is-rescinded.html. Accessed 18 Oct 2016.
50. Dyer O. Company reneges on promise to cut price of toxoplasmosis drug. BMJ. 2015;351:h6472. doi:10.1136/bmj.h6472.
51. Garrison LP, Mansley EC, Abbott TA 3rd, Brenaghan BW, Hay JW, Smeeding J. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report-part II. Value Health. 2010;13:8–13.
52. Hay JW, Seeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report-part I. Value Health. 2010;13:3–7.
53. Mansley EC, Carroll NV, Chen KS, Shah ND, Piech CT, Hay JW, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report-part III. Value Health. 2010;13:14–7.
54. Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, et al. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US Government payers perspectives: the ISPOR Drug Cost Task Force report-part IV. Value Health. 2010;13:18–24.
55. Mycka JM, Dellamano R, Kolassa EM, Wonder M, Ghosh S, Hay JW, et al. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report-part V. Value Health. 2010;13:25–7.